Kapulu MC

Antibodies to PfEMP1 and Variant Surface Antigens: Protection after Controlled Human Malaria Infection in Semi-immune Kenyan Adults.Kinyua AW, Turner L, Kimingi HW, Mwai K, Mwikali K, Andisi C, Sim BKL, Bejon P, Kapulu MC, Kinyanjui SM, Lavstsen T, Abdi AI
J Infect, (2024). :106252

Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.Rosenkranz M, Nkumama IN, Ogwang R, Kraker S, Blickling M, Mwai K, Odera D, Tuju J, Fürle K, Frank R, Chepsat E, Kapulu MC, Study Team CS, Osier FH
Life Sci Alliance, (2024). 7:

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.Nkumama IN, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L, Murungi L, Tuju J, Fürle K, Rosenkranz M, Kimathi R, Njuguna P, Hamaluba M, Kapulu MC, Frank R, Osier FHA
Immunity, (2024). 57:1215-1224

Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.Kapulu MC, Muthumbi E, Otieno E, Rossi O, Ferruzzi P, Necchi F, Acquaviva A, Martin LB, Orindi B, Mwai K, Kibet H, Mwanzu A, Bigogo GM, Verani JR, Mbae C, Nyundo C, Agoti CN, Nakakana UN, Conti V, Bejon P, Kariuki S, Scott JAG, Micoli F, Podda A
Front Immunol, (2024). 15:1340425

The Dantu blood group prevents parasite growth in vivo: Evidence from a controlled human malaria infection study.Kariuki SN, Macharia AW, Makale J, Nyamu W, Hoffman SL, Kapulu MC, Bejon P, Rayner JC, Williams TN
Elife, (2023). 12:e83874

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.Odera DO, Tuju J, Mwai K, Nkumama IN, Fürle K, Chege T, Kimathi R, Diehl S, Musasia FK, Rosenkranz M, Njuguna P, Hamaluba M, Kapulu MC, Frank R, Osier FHA, Abdi AI, Chi PC, de Laurent Z, Jao I, Kamuya D, Kamuyu G, Makale J, Murungi L, Musyoki J, Muthui M, Mwacharo J, Kariuki S, Mwanga D, Mwongeli J, Ndungu F, Njue M, Nyangweso G, Kimani D, Ngoi JM, Musembi J, Ngoto O, Otieno E, Ooko M, Shangala J, Wambua J, Mohammed KS, Omuoyo D, Mosobo M, Kibinge N, Kinyanjui S, Bejon P, Lowe B, Marsh K, Marsh V, Abebe Y, Billingsley PF, Sim BKL, Hoffman SL, James ER, Richie TL, Audi A, Olewe F, Oloo J, Ongecha J, Ongas MO, Koskei N, Bull PC, Hodgson SH, Kivisi C, Imwong M, Murphy SC, Ogutu B, Tarning J, Winterberg M, Williams TN
Sci Transl Med, (2023). 15:eabn5993

Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study.Kapulu MC, Nakakana U, Sciré AS, Sarakinou E, Conti V, Rossi O, Acquaviva A, Necchi F, Obiero CW, Martin LB, Bejon P, Njuguna P, Micoli F, Podda A
Front Immunol, (2022). 13:971866

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.Musasia FK, Nkumama IN, Frank R, Kipkemboi V, Schneider M, Mwai K, Odera DO, Rosenkranz M, Furle K, Kimani D, Tuju J, Njuguna P, Hamaluba M, Kapulu MC, Wardemann H, CHMI-SIKA Study Team, Osier FHA
Nat Commun, (2022). 13:4098

Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.Kimingi HW, Kinyua AW, Achieng NA, Wambui KM, Mwangi S, Nguti R, Kivisi CA, Jensen ATR, Bejon P, Kapulu MC, Abdi AI, Kinyanjui SM, CHMI-SIKA Study Team
Front Immunol, (2022). 13:894770

Shigella-Controlled Human Infection Models: Current and Future Perspectives.Clarkson KA, Porter CK, Talaat KR, Kapulu MC, Chen WH, Frenck RWJr, Bourgeois AL, Kaminski RW, Martin LB
Curr Top Microbiol Immunol, (2022). :

Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt.Mumba N, Njuguna P, Chi P, Marsh V, Awuor E, Hamaluba M, Mauncho C, Mwalukore S, Masha J, Mwangoma M, Kalama B, Alphan H, Wambua J, Bejon P, Kamuya D, Kapulu MC
Front Public Health, (2022). 10:793913

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response.Kapulu MC, Kimani D, Njuguna P, Hamaluba M, Otieno E, Kimathi R, Tuju J, Sim BKL, CHMI-SIKA Study Team
BMC Infect Dis, (2022). 22:86

Antibody Responses to Crude Gametocyte Extract Predict Plasmodium falciparum Gametocyte Carriage in Kenya.Omondi BR, Muthui MK, Muasya WI, Orindi B, Mwakubambanya RS, Bousema T, Drakeley C, Marsh K, Bejon P, Kapulu MC
Front Immunol, (2020). 11:609474

Corrigendum: Immune Responses to Gametocyte Antigens in a Malaria Endemic Population-The African falciparum Context: A Systematic Review and Meta-Analysis.Muthui MK, Kamau A, Bousema T, Blagborough AM, Bejon P, Kapulu MC
Front Immunol, (2020). 11:389

Immune Responses to Gametocyte Antigens in a Malaria Endemic Population-The African falciparum Context: A Systematic Review and Meta-Analysis.Muthui MK, Kamau A, Bousema T, Blagborough AM, Bejon P, Kapulu MC
Front Immunol, (2019). 10:2480

Gametocyte carriage in an era of changing malaria epidemiology: A 19-year analysis of a malaria longitudinal cohort.Muthui MK, Mogeni P, Mwai K, Nyundo C, Macharia A, Williams TN, Nyangweso G, Wambua J, Mwanga D, Marsh K, Bejon P, Kapulu MC
Wellcome Open Res, (2019). 4:66

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity.Kapulu MC, Njuguna P, Hamaluba MM, CHMI-SIKA Study Team
Wellcome Open Res, (2018). 3:155

Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya.Njue M, Njuguna P, Kapulu MC, Sanga G, Bejon P, Marsh V, Molyneux S, Kamuya D
Wellcome Open Res, (2018). 3:39

Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of differing transmission intensity.Goncalves BP, Kapulu MC, Sawa P, Guelbeogo WM, Tiono AB, Grignard L, Stone W, Hellewell J, Lanke K, Bastiaens GJH, Bradley J, Nebie I, Ngoi JM, Oriango R, Mkabili D, Nyaurah M, Midega J, Wirth DF, Marsh K, Churcher TS, Bejon P, Sirima SB, Drakeley C, Bousema T
Nat Commun, (2017). 8:1133